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doi:10.1016/j.jtcvs.2007.11.036Objective: Transluminal in vitro resection of severely calcified human aortic valves
has already been successfully carried out by our group. The aim of this study was
to analyze endovascular laser-assisted resection of human aortic valves in situ in 10
human cadavers.
Material andMethods:After anterolateral minithoracotomy, the aortic valve isolation
chamber system was inserted into the descending aorta and pushed forward translu-
minally into the aortic position to generate a separate operation space between the
subvalvular and the proximal ascending aortic area. After deployment and sealing
of the chamber, stable function with a continuous chamber lavage of 1.58 L/min saline
solution was established (8/10 cases). The endoscopically guided laser fiber was
delivered via the right carotid artery. After fixation of a leaflet by a forceps catheter,
the native leaflets were resected each by a thulium:YAG laser with 20-W power
rating. Macropathology and micropathology of surrounding anatomic structures
were analyzed.
Results: The duration of transluminal positioning and deployment of the aortic valve
isolation chamber took 7.3 6 5.8 minutes. Fluoroscopy confirmed sealed chambers.
The resection was completed in all leaflets and took, on average, 6.06 3.5 minutes per
leaflet. The aortic wall was moderately injured in 4 of 10 cases and the aortic annulus
in two cases with one aortic wall perforation. The surrounding tissue, the coronary os-
tia, the mitral valve, and the left ventricular outflow tract remained unaffected.
Conclusion: This study demonstrates the feasibility of endovascular resection of
human aortic valves in situ. This is a subsequent step toward complete percutaneous
replacement (resection and implantation) of human aortic valves.
F
ifteen years ago, the pioneers of percutaneous valve replacement published
their experimental studies and showed the feasibility of this technology for
the implantation site.1,2 Five years ago, the cardiologist Cribier and his group
performed the first human percutaneous aortic valve implantation.3 This was the onset
of the upcoming percutaneous technique for interventional aortic valve implantation
as a preliminary clinical method. Currently, three transluminal techniques are in clin-
ical testing: the percutaneous approach from the antegrade,3 retrograde,4 and transap-
ical sites of the aortic valve.5,6 For a true replacement of the diseased valve to be
performed percutaneously, the native aortic valve must first be percutaneously re-
sected before the new valve is implanted.
All current experimental and clinical studies of percutaneous aortic valve implan-
tation reported this profound problem: mild to severe paravalvular leakage.3,4,7 In
addition, occlusion of coronary ostia,8,9 embolization of debris,10 migration of the
valved stent,9,11 mild increase of mitral insufficiency,4 and a too small effective
aortic valve area12 have been observed.
As has been pointed out since 2002, percutaneous resection of the diseased and
calcified valve will be necessary if a safe and morphology-oriented consecutive
implantation is to be performed in patients who require a curative approach. This
method will come closer to the high conventional surgical standard.12The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1081
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AVIC 5 aortic valve isolation chamber
After a variety of resectionmethods had been tested, endo-
scope-guided resection of aortic valves could be successfully
undertaken in 2005 with a high-pressure water-stream scalpel
in an in vitro model. An aortic valve isolation chamber
(AVIC; with support of STI Deutschland GmbH, Henstedt-
Ulzburg, Germany) has been additionally developed to avoid
the escape of any debris during valve excision, consequently
preventing central or peripheral embolization.13
The aim of this study was to analyze the laser-assisted en-
dovascular resection of sclerotic human aortic valves in situ
in 10 human cadavers using a thulium:YAG laser with
a 20-W power rating.
Material and Methods
The AVIC
So that the escape of debris during the resection process can be
avoided, the aortic valve must be isolated. The AVIC has been de-
veloped to generate a shielded room between the supravalvular and
the subvalvular balloons. The AVIC consists of a main catheter with
six working channels and three polyethylene balloons (Figure 1, A
and B, and Figure 2, A).
The overall size of this tool is more than 22F, which precludes its
insertion via the groin. Therefore, two parallel approaches are re-
quired.
The pressure of AVIC balloons was monitored online to prevent
unnoticed pressure decrease caused by leakage with a subsequent
unstable chamber function. A permanent lavage of 1.58 L/min
was established by a rotary pump (Stockert Instruments GmbH,Mu-
nich, Germany) to ensure a clear view during the resection process.
Additionally, the debris was washed out.
To facilitate insertion of AVIC and prevent blood leakages dur-
ing the resection, we developed a special port system for temporal
implantation into the distal descending aorta during the procedure
(Figure 1, C).
Aortic Valve Resection Tool
Themild-to-severely sclerotic aortic valveswere resected by a diode-
pumped continuous-wave thulium:YAG laser (ITL 2000, Lisa Laser
Products OHG, Katlenburg-Lindau, Germany) emitting at a wave-
length of 2.01 mm with 20-W power rating. Laser power was trans-
mitted via a commercially available 365-mm quartz fiber (core Ø,
CeramOptec GmbH, Bonn, Germany). The fiber was controlled by
a flexible endoscope (Richard Wolf GmbH, Knittlingen, Germany)
with an outer diameter of 7.5F and a length of 600 mm. The front
part of the endoscope (40 mm) was operated by manual control.
The endoscope was inserted via an additional port system (8F)
through the right carotid artery.
Human Preparations
Before death, these subjects gave written consent to the Institute of
Anatomy of the Christian-Albrechts University in Kiel to donate1082 The Journal of Thoracic and Cardiovascular Surgery c Matheir bodies for research (n 5 10; age, 73 6 10 years; gender, 5
female, 5 male; weight, 66.4 6 10.2 kg; height, 169.7 6 7.6
cm). Our study was approved by the Ethics Committee of the
University of Kiel from November 24, 2004 (D 434/04). This study
was realized in agreement with the basic principles of ethics (Basic
Constitutional Law of the Federal Republic of Germany, x1).
AVIC Deployment
For AVIC installation, two approaches were required: a thoracic
aortic access (descending aorta) and a right common carotid artery
access. Therefore, a left-sided lateral minithoracotomy was per-
formed (ICR [intercostal space] 4/5). The descending aorta was pre-
pared with two purse-string sutures. To optimize AVIC installation,
we implanted the port system into the descending aorta. Then, the
AVIC was positioned via a guide wire into the aortic valve position
(Ø 0.035 inch; Terumo Europe Interventional Systems, Guyancourt
Cedex, France). The subvalvular balloons were positioned below
the aortic valve and the supravalvular balloon was placed between
the brachiocephalic artery and the left common carotid artery (Fig-
ure 2, A). After inflation of the subvalvular and supravalvular bal-
loons under fluoroscopic and endoscopic control, the resection
chamber system was filled with saline solution.
AVIC Testing
Three pressures were separately monitored online: the subvalvular
balloon pressure, the supravalvular balloon pressure, and the
resection chamber pressure. In case of balloon or chamber leakage,
the experiment would have been stopped and the chamber integrity
re-established. After the AVIC had been filled with water, the inflow
and outflow of the chamber was controlled to obtain a stable
chamber lavage (flow of 1.58 L/min). In addition, the in-chamber
pressure was measured to adjust the chamber perfusion.
Endovascular Aortic Valve Resection
The experimental setup is shown in Figure 2, A. The endoscope was
controlled by a cardiac surgeon. Three assistants handled the forceps
catheter, endoscopic visualization, chamber perfusion, and pres-
sures of the AVIC (balloons and chamber).
The endoscope with the in-lying laser fiber was placed in the
AVIC via the right common carotid artery. The forceps catheter
was inserted via the AVIC system and the visualization was also
realized via theAVIC system. The aortic leaflets, all moderately scle-
rosed, were gripped and held in place (one by one) with the forceps
catheter (Ø 1.3 mm, Richard Wolf). The resection was performed
with a continuous-wave laser source (wavelength at 2.01 mm) with
a distal power level at 20 W transmitted via quarz fiber (365-mm
core diameter). The resection process was video controlled (with
a 30-inch television) and digitally recorded. The leafletswere excised
2 to 3 mm from the insertion of the annulus (Figure 2, B and C).
Fragments of the resected leaflets were removed through the AVIC.
Analyzed Parameters
The procedure time (minithoracotomy and dissection of the aorta
and the right carotid artery), deployment time for the port, and instal-
lation time for the AVIC were recorded (in minutes). The handling
of the port, the AVIC, and the auxiliary tools (guidance, deploy-
ment, fixation, visualization, and removal) was analyzed. The seal-
ing of the AVIC was verified with balloon- and chamber-pressurey 2008
Quaden et al Surgery for Acquired Cardiovascular DiseaseFigure 1. A, Aortic valve isolation
chamber (AVIC) prototype (STI Deutsch-
land GmbH, Henstedt-Ulzburg, Ger-
many). B, Inflated subvalvular
balloons. C, Port system for descending
aortic approach.A
CDmonitoring (10/10) and fluoroscopy (5/10). Visualization was
accomplished endoscopically.
The duration of the laser resection required for one leaflet (min-
utes), size of the resected valve area (cm2), size of the excised frag-
ments (cm2), resistance of the AVIC balloons, and any lesions
observed in the surrounding tissue within 40 mm of the annulus
were protocoled: macropathology and micropathology were ana-
lyzed (hematoxylin–eosin staining). The laser handling (resection
accuracy, fiber flexibility, and usability of the laser source) were an-The Journal of Thoralyzed. The use of the laser-guiding endoscope and the forceps cath-
eter (guidance, flexibility, usability, and operating accuracy) were
analyzed. All data are expressed as mean 6 SD.
Results
AVIC Setup
The surgical procedure took 90 minutes (median, range 13–
135 minutes) and the deployment of the port system took onFigure 2. A, Experimental setup with
a deployed AVIC system with its supra-
valvular (1) and subvalvular (2)
balloons, the endoscopic guided laser
fiber (3), and the grab catheter (4). B,
Resection sequence: the endoscope-
guided laser fiber (3) with the aiming
beam (red point, 5) in a sealed AVIC in
a human body with a fixed aortic cusp
by the grab catheter (4). C, Resected
aortic valve from the left ventricular
side (AO, aortic orifice; MV, mitral
valve). D, Annulus damage (i, aortic
side; ii, annulus tissue) (hematoxylin
and eosin, 203).acic and Cardiovascular Surgery c Volume 135, Number 5 1083
Surgery for Acquired Cardiovascular Disease Quaden et al
A
CDaverage 2.76 0.8 minutes. After guide wire positioning, the
AVIC was installed within 7.5 6 5.8 minutes. Constant bal-
loon and chamber pressures as well as fluoroscopy indicated
a stable chamber function (8/10). The visualization was
focused on the aortic valve.
AVIC Testing
AVIC testing showed the following pressures on average:
constant chamber pressure in 7 of 10 cases, subvalvular
balloon pressure 182.8 6 52.3 mm Hg, and supravalvular
pressure 179 6 82.2 mm Hg. The sealing efficiency was an-
alyzed.
Resection Process
The resection process took a mean of 6.0 6 3.6 minutes per
cusp. Macropathology and micropathology demonstrated su-
perficial lesions and one complete perforation of the aortic
wall (Figure 2, D). The mitral valve, left ventricular outflow
tract, and endomyocardium remained unaffected.
Debris Analysis
The leaflets were resected and removed in toto. On average,
the excised leaflet size was 1.4 6 0.5 cm2.
Evaluation of AVIC and the Resection Tools
Visualization was adequate to display the structures of inter-
est during the entire experiment. The endoscope allowed
acceptable guidance of the laser fiber during resection. Oper-
ating the forceps catheter was difficult owing to lack of steer-
ability. The forceps possesses only open-and-close function
and no direction control. Although the AVIC was pretested
successfully in numerous preliminary tests, a few construc-
tion problems occurred: dismantling of bonding surfaces
(3/10), twisting of tubes (1/10), and leakage of subvalvular
balloons (3/10).
The supravalvular balloon remained stable in all cases (10/
10). One of the two subvalvular balloons ruptured in two
cases.
Discussion
In this study, the research focus was the feasibility and the
mechanical functionality in human anatomy. We have suc-
cessfully demonstrated that endovascular resection of the
diseased aortic heart valve is possible. Nevertheless, the ex-
perimental work using this setup should be considered
preliminary and further built on in the future.
AVIC
An AVIC must be used to avoid the embolization resulting
from calcified particles. This catheter-based system was
easily deployed and the chamber could be sealed in all
cases. The ongoing enhancement of this system is moving
toward minimization and more flexibility for in vivo
deployment.1084 The Journal of Thoracic and Cardiovascular Surgery c MResection
The results demonstrate that endoluminal resection with per-
cutaneously inserted instruments is feasible. Except for the
perforation of the aortic wall seen in one case, the macro-
scopic and microscopic analysis showed only mild damage.
However, efforts must be undertaken to improve the tracta-
bility and the preciseness of the resection tools and to shorten
the required resection time. In the case of highly calcified aor-
tic valves, the implemented continuous laser was not effec-
tive. However, it has already been demonstrated that these
human calcified valves can be cut by a high-pressure water-
stream scalpel.13 The development of a newly designed,
more flexible, smaller water scalpel is ongoing as is the en-
hancement of a suitable laser source.
Although research on the optimal valve substitute is still
ongoing, endovascular techniques have recently been pro-
posed as alternative therapies for both aortic and mitral
disease. In contrast to robotics, the percutaneous valve tech-
niques are still simpler than surgery. The opportunity to have
an aortic valve replaced (resected and implanted) without se-
dation by a vascular approach is undoubtedly appealing to the
patient.
The latest data showed very good procedural and short-
term results for pulmonary valve implantation14 and satisfac-
tory results for percutaneous aortic valve implantation.6
Nevertheless, despite the successes with percutaneous
aortic valve implantation, optimism should be tempered.
The aortic valve implantation series presented by Webb
and coworkers4 evidenced some major drawbacks, such as
paravalvular leakage (in 13/14 cases), which is caused by
the persistence of empty space between the percutaneously
implanted valve and the native valve owing to calcifications.
This was observed in the majority of patients. Moreover, an
increase in mitral insufficiency (from pre-procedural 12 to
13 of 4 grades after the procedure) has been observed on av-
erage in the overall patient cohort. In addition, a coronary
flow obstruction caused by a bulky calcified leaflet that was
displaced by the valved stent occurred in 1 patient and athe-
roembolism of calcic debris during the necessary valvulo-
plasty and the positioning of the device happened in
another 2 patients (1 stroke).4
In fact, some intraprocedural complications, such as ejec-
tion of the valved stent into the ascending aorta at the time of
balloon inflation, have been reported a few times by two
groups.4,15 Hemodynamic collapse after balloon predilation
also occurred.15 One could argue that this is all due to the
stainless steel stent, which is often used for valved stent
implantation. The option of using a valved nitinol stent has
resulted in even more cardiovascular events and a higher co-
morbidity.16 Finally, several technical difficulties, that is, in-
ability to cross the stenotic valve or unsuccessful prosthesis
deployment, have been described for both the antegrade
and retrograde approaches,3,4,17 so that transapical access
has been discussed.18ay 2008
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CDEven if the device-related complications and the morbid-
ity of this implantation procedure in these high-risk patients
is reduced over time (Webb’s group4 already has fewer prob-
lems than the first data reported by Cribier and associates3),
the fundamental problems will not be easily overcome: the
necessary balloon valvuloplasty (with its own high mortality
and especially morbidity rate) and the foreseen short-term du-
rability of the implanted pericardial valves (dysfunction after
high pressurized compression and re-expansion) are huge
problems.
In contrast to the percutaneous aortic approach, transapi-
cal implantation seems to be more favorable. This direct ap-
proach allows better valved stent deployment and has a lower
complication rate, especially in patients with generalized ath-
erosclerosis. The short-term results are well accepted clini-
cally.5,6 Therefore, evaluation of this approach is ongoing
and remains encouraging.
In 2007, the device was optimized by numerous improve-
ments, and this has also significantly improved the patient’s
outcome. New stents have been developed, from balloon-
expandable19 to self-expanding stents,20 and new applicator
systems have been designed for an antegrade,21 retrograde,4
or transapical approach.5 In addition, the preinterventional
screening of the patients became more important owing to
the fact that calcified peripheral and central vessels and
highly calcified aortic valves dramatically increase the risk
of periprocedural and postprocedural complications, espe-
cially mortality.22-24
To treat patients with moderately to highly calcified
aortic valves percutaneously and at the same time adhere
as much as possible to the surgical gold standard, the
valve must be resected before the new valve can be im-
planted.11 However, it appears from the present experience
that is important to leave an anchoring area (annulus plus
a small rim of calcified leaflet) for the fixation of the new
valved stent.
In a recent in vitro study, Flecher and associates8
demonstrated that coronary flow was significantly reduced
after implantation of a valved stent owing to coronary ostial
irritation by the left-in-place native leaflets. After removal
of these leaflets, the flow reduction was no longer present.
Earlier in vivo studies showed diametrically different
results: no interference concerning coronary ostia and the
native valve appeared after valve implantation25 versus
complete ebbing of myocardial perfusion owing to stent
position.26
Limitations
Owing to the experimental appendage, the presented system
is not yet ready to be used in vivo, but the results will
pave the way for future enhancement. For instance, in the
next study, the coronary arteries will be blocked by cardio-
plegia catheters to prevent any debris from entering the
ostia.The Journal of ThoraThe improvement of the resection chamber technology is
ongoing, especially the sealing method for a beating heart
modus.
The described approach via the distal descending aorta
and the carotid artery must be combined into a single
approach, which will be reached after minimization of the
overall resection catheter.
Currently, on-pump aortic valve replacement is carried
out with very low mortality and acceptable morbidity in
the vast majority of patients.24 Very few cases are rejected
owing to too high a risk from the presence of significant
comorbidity. Hence, this procedure remains the gold
standard for the treatment of aortic valve stenosis and/or
regurgitation.
Future Prospects
Extensive research is still required to achieve clinical off-
pump aortic valve resection.27 In this study, we have shown
the feasibility of endovascular aortic valve resection in a hu-
man preparation. The next step will be to resect the aortic
valve under cardiopulmonary bypass support in an arrested
heart with cardioplegic myocardial arrest. The end goal is
to perform the resection with blood flowing through a central
lumen of the resection chamber in a beating heart, without
cardiopulmonary bypass.
Currently, novel microsystemic technology (actuator-
based) for improved guidance of the resection tool is under
construction. In our future experiments, only one ablation
device containing all instruments will be applied for the
transapical access and later for the percutaneous approach.
Conclusions
The present study demonstrates the feasibility of endovascu-
lar laser-assisted resection under sealed conditions of the aor-
tic valve in situ. Conventional aortic valve surgery is still the
gold standard to treat aortic valve disease. In contrast, percu-
taneous valved stent implantation is very much a palliative
approach.
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